Melanotan I

Melanotan I (afamelanotide) is a synthetic tridecapeptide analog of human α-melanocyte-stimulating hormone (α-MSH) developed by Clinuvel Pharmaceuticals. The molecular structure is [Nle4, D-Phe7]-α-MSH: the parent α-MSH sequence (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) with methionine at position 4 replaced by norleucine and L-phenylalanine at position 7 replaced by D-phenylalanine. These two amino acid substitutions increase potency at the melanocortin-1 receptor (MC1R) by approximately 100-fold and extend biological half-life compared to natural α-MSH. The compound is the only melanocortin receptor agonist peptide with regulatory approval anywhere. The EMA approved afamelanotide as Scenesse on December 22, 2014, and the FDA approved Scenesse on October 8, 2019, both for treatment of erythropoietic protoporphyria (EPP) in adult patients with a history of phototoxic reactions. Scenesse is administered as a 16 mg controlled-release subcutaneous PLGA rod implant every 2 months. Off-label cosmetic use for tanning is widespread through research-chemical channels, but these preparations are unregulated, lack the controlled-release implant formulation, and have variable purity.

Development History

Afamelanotide originated from research by Victor Hruby and colleagues at the University of Arizona in the 1980s on melanocortin structure-activity relationships. The [Nle4, D-Phe7]-α-MSH analog was identified as having approximately 100-fold higher potency at MC1R than natural α-MSH and extended biological half-life through resistance to proteolytic degradation. The compound was initially designated NDP-MSH.

Clinuvel Pharmaceuticals (originally Epitan, founded in Australia) licensed the compound under the development name CUV1647 and pursued pharmaceutical development. The Scenesse implant formulation was developed to provide controlled release and overcome the short native half-life.

Regulatory milestones:

• December 2014: EMA marketing authorization for Scenesse in the European Union for EPP
• October 2019: FDA approval of Scenesse for EPP (first US approval of any melanocortin agonist peptide)
• Post-approval: continued use in EPP patients and ongoing research for additional indications (vitiligo, polymorphic light eruption, solar urticaria, Hailey-Hailey disease)

Mechanism of Action

Afamelanotide binds the melanocortin-1 receptor (MC1R) on melanocytes and other dermal cells with high affinity. MC1R is a Gs-coupled GPCR that signals through adenylyl cyclase activation, increased cAMP, and PKA activation. Downstream effects include:

Melanogenesis stimulation: MITF activation, tyrosinase and TRP-1/TRP-2 upregulation, increased eumelanin synthesis, shifted balance from pheomelanin to eumelanin.

Photoprotective effects: Eumelanin absorbs UV radiation across UVA and UVB ranges, scattering of light, neutral density filter effect, free radical scavenging.

Anti-inflammatory effects: Reduced cytokine production, reduced prostaglandin production, effects on immune cells expressing melanocortin receptors.

DNA repair and antioxidant effects: Enhanced nucleotide excision repair, antioxidant gene expression, reduced reactive oxygen species generation.

Erythropoietic Protoporphyria: The Approved Indication

EPP is a rare inherited disorder of heme biosynthesis. The most common form involves ferrochelatase (FECH) deficiency, leading to accumulation of protoporphyrin IX in erythrocytes, plasma, and skin. When EPP patients are exposed to visible light, protoporphyrin generates reactive oxygen species, producing immediate phototoxic reactions characterized by burning pain, swelling, and inflammatory damage within minutes of light exposure. The condition is often described as one of the most painful skin conditions known.

Before Scenesse approval, there was no effective treatment for EPP. Beta-carotene, N-acetyl-L-cysteine, vitamin C, and other interventions showed minimal benefit in systematic reviews.

The Langendonk 2015 NEJM trial demonstrated efficacy of Scenesse in EPP. Two multicenter, randomized, double-blind, placebo-controlled trials of 16 mg subcutaneous implants enrolled adults with EPP. The primary endpoint was time spent in direct sunlight without pain over a 6-month period. Scenesse-treated patients spent significantly more time in sunlight without pain compared to placebo (mean difference approximately 116 hours over 6 months in one trial). Quality of life measures also improved.

Real-world post-approval evidence from Wensink 2020 JAMA Dermatology in 117 Dutch EPP patients confirmed clinically meaningful benefit in routine practice.

Research in Other Indications

Afamelanotide has been investigated for additional indications: polymorphic light eruption (some trial evidence of benefit), solar urticaria (case series and trial data showing benefit), vitiligo (studies in combination with NB-UVB phototherapy showed enhanced repigmentation, NCT01430195), Hailey-Hailey disease (case series showed potential benefit), variegate porphyria and porphyria cutanea tarda, and phototoxic drug reactions.

The expanded indication picture remains primarily investigational, with EPP as the only approved use.

Off-Label Cosmetic Tanning Use

Beyond pharmaceutical Scenesse, Melanotan I is widely sold through research-chemical channels for cosmetic tanning. These preparations are not the Scenesse pharmaceutical formulation, lack the PLGA controlled-release implant technology, are typically injected as subcutaneous solutions (often daily or every-other-day at 0.16-1 mg per injection), have unverified purity and identity, lack regulatory oversight, and may contain contaminants, endotoxins, or incorrect peptides. They have been associated with reports of melanoma in nevi, kidney damage, rhabdomyolysis, and serious infections from contaminated preparations or needle sharing.

The off-label cosmetic market for melanotan peptides exists despite regulatory warnings from the FDA, UK MHRA, and other agencies about safety concerns and legality.

Distinction from Melanotan II

Melanotan I and Melanotan II are commonly conflated but are chemically and pharmacologically distinct compounds:

Melanotan I (afamelanotide): Linear 13-amino-acid peptide, selective for MC1R, FDA and EMA approved as Scenesse, limited systemic side effects, slower onset of effects.

Melanotan II: Cyclic 7-amino-acid peptide (Ac-Nle-c[Asp,His,D-Phe,Arg,Trp,Lys]-NH2), broader melanocortin receptor activity, crosses the blood-brain barrier, more side effects (nausea, flushing, erectogenic effects through MC4R), no regulatory approval anywhere, cheaper to manufacture.

Regulatory Status

• FDA: Approved October 8, 2019 as Scenesse for erythropoietic protoporphyria in adults (NDA 210797). Orphan drug designation. REMS program for controlled distribution
• EMA: Approved December 22, 2014 for the same indication
• TGA (Australia): approved for EPP
• WADA: Prohibited under Section S2 (Peptide hormones and related substances) for all melanocortin peptide agonists
• Research-chemical channels: principal source for off-label use, unregulated

Afamelanotide acts as a high-affinity, long-acting agonist at the melanocortin-1 receptor (MC1R) with some activity at MC3R, MC4R, and MC5R.

Receptor Pharmacology

The melanocortin receptor family consists of five GPCRs (MC1R through MC5R) with distinct tissue distributions and physiological functions:

• MC1R: skin, melanocytes, immune cells. Principal mediator of skin pigmentation
• MC2R: adrenal cortex. Mediates ACTH effects on cortisol production
• MC3R: hypothalamus, immune cells. Energy balance, inflammation
• MC4R: hypothalamus, brain. Appetite, sexual function
• MC5R: exocrine glands. Various functions including sebum production

Afamelanotide shows highest affinity for MC1R, with approximately 100-fold higher potency than natural α-MSH. The Nle4 and D-Phe7 substitutions confer protease resistance and modified receptor binding characteristics.

Some receptor binding at MC3R, MC4R, and MC5R occurs but is less clinically significant than the MC1R effects. The relatively poor blood-brain barrier penetration of the linear 13-amino-acid peptide limits central nervous system MC4R activation (distinguishing it from Melanotan II).

MC1R Signaling and Melanogenesis

MC1R activation triggers Gs-coupled signaling: adenylyl cyclase activation, increased intracellular cAMP, PKA activation, CREB phosphorylation, MITF gene transcription, MITF-driven expression of tyrosinase and tyrosinase-related proteins, increased melanin synthesis, and shifted eumelanin/pheomelanin ratio toward photoprotective eumelanin.

The downstream melanogenesis cascade in melanocytes increases the number, size, and activity of melanosomes. Mature melanosomes are transferred from melanocytes to surrounding keratinocytes through dendritic processes, distributing pigment throughout the epidermis.

Non-Pigmentation Effects

Beyond melanogenesis, MC1R activation produces:

Anti-inflammatory effects: reduced NF-κB activation, decreased pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6, IL-8), reduced prostaglandin production.

Antioxidant effects: increased expression of antioxidant enzymes, direct radical scavenging by eumelanin itself, reduced reactive oxygen species generation.

DNA repair: enhanced nucleotide excision repair pathway activity, increased XPC and other repair gene expression.

Anti-apoptotic effects: reduced UV-induced melanocyte apoptosis.

Pharmacokinetics of Scenesse

The Scenesse 16 mg PLGA implant provides controlled release:

• Implant dimensions: 1.7 cm long, 1.45 mm diameter rod
• Material: poly-lactic-co-glycolic acid (PLGA) biodegradable matrix
• Release duration: approximately 5 days for the active peptide
• Tmax: approximately 36 hours after implantation
• Apparent half-life: approximately 15 hours
• Pigmentation duration: approximately 2 months
• Administration interval: every 2 months

Comparison with Other Melanocortin Approaches

Setmelanotide (Imcivree): selective MC4R agonist approved for genetic obesity syndromes.

Bremelanotide (Vyleesi): MC4R-active melanocortin peptide approved for hypoactive sexual desire disorder.

Melanotan II: cyclic 7-amino-acid α-MSH fragment analog. Different molecule from Melanotan I.

Natural α-MSH: the endogenous ligand. Limited therapeutic use due to short half-life and lower potency.

Effects documented in approved Scenesse use for EPP:

• Reduced incidence and severity of phototoxic reactions
• Increased pain-free time in direct sunlight (Langendonk 2015 NEJM, approximately 116 hours additional over 6 months versus placebo)
• Improved quality of life measures
• Increased skin pigmentation (eumelanin-dominant)
• Real-world clinical effectiveness confirmed in Wensink 2020 JAMA Dermatology and other post-approval studies

Effects in research for additional indications:

• Repigmentation in vitiligo combined with NB-UVB phototherapy
• Reduced photosensitivity in polymorphic light eruption
• Symptom improvement in solar urticaria
• Case reports of benefit in Hailey-Hailey disease

Effects in off-label cosmetic tanning use:

• Gradual skin darkening over 2-3 weeks of loading doses
• Increased UV tolerance
• Reduced sunburn risk reported anecdotally
• More natural and even tan compared to Melanotan II
• Persistence of effects for weeks after cessation

Adverse effects observed in clinical trials and post-marketing surveillance:

• Implant site reactions (pain, swelling, erythema, infection)
• Fatigue
• Nausea
• Headache
• Generalized skin hyperpigmentation
• Darkening of pre-existing nevi (moles)
• Darkening of ephelides (freckles)
• Serious hypersensitivity reactions including anaphylaxis (postmarket)
• Rare reports of melanoma in pigmented lesions

Honest evidence framing: Melanotan I represents one of the more rigorously validated peptide therapeutics, with FDA approval based on randomized controlled trials, EMA approval, post-marketing safety surveillance, and real-world evidence in EPP patients. For the approved indication, Scenesse provides clinically meaningful but partial benefit. The compound's mechanism is well-characterized. For off-label cosmetic tanning, the situation is fundamentally different: research-chemical Melanotan I lacks the controlled-release implant formulation, quality oversight, and safety monitoring infrastructure of Scenesse. The pharmacological effects are similar but the safety profile of unregulated preparations is substantially worse, with documented cases of contaminated preparations, injection site infections, and serious adverse events. The theoretical melanoma concern from darkening of pre-existing nevi has not been epidemiologically confirmed but warrants the FDA-required twice-yearly skin examinations in Scenesse patients. Off-label cosmetic users typically do not have this monitoring.

Important note: Scenesse has an FDA-approved dose for erythropoietic protoporphyria. Off-label doses described below for research-chemical Melanotan I have no clinical validation.

FDA-Approved Dose (Scenesse)

• Indication: erythropoietic protoporphyria in adults
• Dose: 16 mg controlled-release subcutaneous implant
• Frequency: every 2 months
• Administration: by healthcare provider in REMS-certified specialty practice
• Implant placement: supraspinatous fossa above the iliac crest
• Implant retention: approximately 5 days for peptide release; some practitioners remove after 30-60 days

Off-Label Research-Chemical Dosing (No Clinical Validation)

Cosmetic tanning protocols using research-chemical Melanotan I:

• Loading phase: 0.16-0.5 mg subcutaneously daily for 1-2 weeks
• Maintenance phase: 0.16-0.5 mg subcutaneously 2-3 times per week
• Total course: variable, ranging from weeks to months
• Reconstitution: typically with bacteriostatic water
• Storage: refrigerated after reconstitution

These off-label doses have no FDA validation and no controlled-release formulation. The injection profile produces very different pharmacokinetics from the Scenesse implant.

Routes

• Subcutaneous implant: the FDA-approved route. Provides controlled release
• Subcutaneous injection of free peptide: off-label route. Different pharmacokinetics
• Other routes: not used in approved or research-chemical protocols

Stacking Considerations

In the FDA-approved EPP indication: Scenesse is used as monotherapy. No standard combinations.

In off-label cosmetic tanning: occasionally combined with UV exposure to potentiate effects. This combination has theoretical concerns about increased melanoma risk.

Special Populations

• Pregnancy: contraindicated. No adequate human safety data
• Breastfeeding: avoid
• Pediatric: not approved for children. Limited data
• Active melanoma or other skin malignancy: contraindicated
• History of melanoma: caution, may be contraindicated depending on clinical context
• Multiple atypical nevi: requires careful monitoring
• Hypersensitivity to afamelanotide or components: contraindicated
• Athletes: WADA-prohibited. Therapeutic Use Exemption required for medical use

Adverse effects observed in Scenesse clinical trials and post-marketing surveillance:

Common (≥5%):

• Implant site reactions: pain, swelling, erythema, induration
• Headache
• Fatigue
• Skin hyperpigmentation (expected pharmacological effect)
• Nausea
• Back pain
• Upper respiratory tract infection

Less common but clinically significant:

• Darkening of pre-existing nevi (moles) and ephelides (freckles)
• New pigmented lesions
• Vomiting
• Dizziness
• Insomnia
• Implant site infection

Serious adverse events (reported in postmarket use):

• Hypersensitivity reactions including anaphylaxis
• Possible association with melanoma in darkened lesions (causal link not established)
• Severe implant site infections

Research-chemical specific concerns (not seen with Scenesse pharmaceutical):

• Contaminated preparations causing severe injection site infections
• Endotoxin reactions
• Renal failure (reported with some research-chemical preparations)
• Rhabdomyolysis (reported with some research-chemical preparations)
• Bloodborne disease transmission from needle sharing
• Variable purity affecting dosing accuracy
• Identity verification failures (wrong peptide)

Theoretical concerns:

• Melanoma: chronic MC1R activation could theoretically increase melanoma risk in genetically susceptible individuals. The FDA requires twice-yearly full body skin examinations for Scenesse patients
• Atypical nevi progression: pre-existing dysplastic nevi may darken and become more difficult to monitor
• Long-term repeated dosing effects: most clinical data covers up to 5 years of repeated dosing

Contraindications

• Hypersensitivity to afamelanotide
• Active melanoma
• Other active skin malignancy
• Pregnancy
• Breastfeeding
• Pediatric use (under 18)
• Severe hepatic impairment (caution)

Drug Interactions

• Photosensitizing drugs: potential modulation of phototoxicity
• Other melanocortin agonists: theoretical additive effects
• Immunosuppressants: theoretical interactions through melanocortin pathway immune effects
• No major established drug interactions

Monitoring Requirements

For FDA-approved Scenesse use: twice-yearly full body skin examination by dermatologist, documentation of all nevi, photography of suspicious lesions, histological evaluation of any changing lesions, patient education on self-examination.

For off-label research-chemical use, these monitoring practices are typically absent, increasing risk.

Athletes: WADA-prohibited. Detection methods established. Therapeutic Use Exemption available for medical use with EPP diagnosis documentation.

Melanotan I (Scenesse/afamelanotide) is in the melanocortin receptor agonist class. Its closest comparators within and near the peptide space:

• Melanotan II (mentioned here for clarity): cyclic 7-amino-acid melanocortin analog. Different molecule from Melanotan I despite similar name. Broader receptor activity, more side effects, no regulatory approval. Often confused with Melanotan I in research-chemical markets
• Setmelanotide (Imcivree): selective MC4R agonist FDA-approved for genetic obesity syndromes. Different target receptor (MC4R vs MC1R)
• Bremelanotide (Vyleesi): MC4R-active melanocortin peptide FDA-approved for hypoactive sexual desire disorder

In the broader peptide space:

• Epitalon: Khavinson pineal tetrapeptide. Unrelated mechanism but sometimes mentioned in anti-aging contexts
• BPC-157: gastrointestinal pentadecapeptide with healing properties. Different mechanism but commonly stacked in off-label peptide protocols
• TB-500: thymosin beta-4 fragment with tissue healing properties

For the FDA-approved EPP indication, Scenesse is used as monotherapy with no standard pharmaceutical combinations.

In off-label cosmetic tanning use (not recommended given safety concerns), Melanotan I is sometimes combined with:

• UV exposure (tanning beds, sunlight): theoretical synergy but increased melanoma risk
• Other peptides marketed for anti-aging: no validated synergies
• Anabolic-androgenic steroids: combined in some bodybuilding contexts. Additional safety concerns

Combinations to absolutely avoid:

• Active melanoma or skin cancer: contraindicated
• History of multiple atypical nevi without monitoring: significant melanoma risk concern
• Pregnancy and breastfeeding: avoid
• Pediatric use: not approved, avoid
• Concurrent immunosuppressant use without medical supervision: theoretical concerns
• Athletes subject to WADA testing: prohibited, requires TUE for medical use

The most actionable framing of Melanotan I in 2026: this is the only melanocortin receptor agonist peptide with FDA approval, available as Scenesse (Clinuvel Pharmaceuticals) for treatment of erythropoietic protoporphyria in adults. The 16 mg controlled-release subcutaneous PLGA implant administered every 2 months provides clinically meaningful benefit for EPP patients, increasing pain-free light exposure time and improving quality of life. The mechanism (MC1R agonism, eumelanin induction, antioxidant effects, anti-inflammatory effects, DNA repair enhancement) is well-characterized. For EPP patients, Scenesse is a well-validated treatment option administered in REMS-certified specialty practices with required twice-yearly skin monitoring. For off-label cosmetic tanning use, the situation is substantially different: research-chemical Melanotan I lacks the controlled-release formulation, quality oversight, and safety monitoring infrastructure of Scenesse. The pharmacological effects are similar (increased skin pigmentation, photoprotection) but the safety profile of unregulated preparations is substantially worse with documented cases of contaminated preparations, serious infections, and isolated reports of melanoma in darkened nevi. The theoretical melanoma concern from chronic MC1R activation warrants the FDA-required skin monitoring in Scenesse patients, which off-label users typically lack. WADA prohibition is unambiguous for athletes. For cosmetic tanning, evidence-based alternatives (sunless tanning products, professional spray tans, makeup-based bronzing) avoid the pharmacological safety concerns. Melanotan I should not be confused with Melanotan II, a different and unregulated peptide with broader receptor activity and more side effects.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.